Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

prostate-specific membrane antigen

  • 
    A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
    You have access
    A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
    Monica Abghari-Gerst, Wesley R. Armstrong, Kathleen Nguyen, Jeremie Calais, Johannes Czernin, David Lin, Namasvi Jariwala, Melissa Rodnick, Thomas A. Hope, Jason Hearn, Jeffrey S. Montgomery, Ajjai Alva, Zachery R. Reichert, Daniel E. Spratt, Timothy D. Johnson, Peter J.H. Scott and Morand Piert
    Journal of Nuclear Medicine April 1, 2022, 63 (4) 567-572; DOI: https://doi.org/10.2967/jnumed.121.262412
  • The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
    You have access
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
    Liang Dong, Yun Su, Yinjie Zhu, Mark C. Markowski, Mei Xin, Michael A. Gorin, Baijun Dong, Jiahua Pan, Martin G. Pomper, Jianjun Liu, Kenneth J. Pienta, Wei Xue and Steven P. Rowe
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 248-252; DOI: https://doi.org/10.2967/jnumed.121.262411
  • Kidney Doses in <sup>177</sup>Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
    You have access
    Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
    Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer and Juri Ruf
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 253-258; DOI: https://doi.org/10.2967/jnumed.121.262245
  • Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
    You have access
    Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
    Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982
  • You have access
    Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
    Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
  • Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
    You have access
    Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
    Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434
  • Positive Predictive Value and Correct Detection Rate of <sup>18</sup>F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
    You have access
    Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
    Maythinee Chantadisai, Gabriel Buschner, Markus Krönke, Isabel Rauscher, Thomas Langbein, Stephan G. Nekolla, Kilian Schiller, Matthias M. Heck, Tobias Maurer, Alexander Wurzer, Hans-Juergen Wester, Calogero D’Alessandria, Wolfgang Weber and Matthias Eiber
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 968-974; DOI: https://doi.org/10.2967/jnumed.120.255661
  • Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with <sup>67</sup>Cu
    You have access
    Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu
    Lachlan E. McInnes, Carleen Cullinane, Peter D. Roselt, Susan Jackson, Benjamin J. Blyth, Ellen M. van Dam, Nicholas A. Zia, Matthew J. Harris, Rodney J. Hicks and Paul S. Donnelly
    Journal of Nuclear Medicine June 1, 2021, 62 (6) 829-832; DOI: https://doi.org/10.2967/jnumed.120.251579
  • <sup>177</sup>Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio
    You have access
    177Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio
    Hsiou-Ting Kuo, Kuo-Shyan Lin, Zhengxing Zhang, Carlos F. Uribe, Helen Merkens, Chengcheng Zhang and François Bénard
    Journal of Nuclear Medicine April 1, 2021, 62 (4) 521-527; DOI: https://doi.org/10.2967/jnumed.120.250738
  • You have access
    The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
    Sara Harsini, Heather Saprunoff, Tina Alden, Behnoud Mohammadi, Don Wilson and François Bénard
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 81-87; DOI: https://doi.org/10.2967/jnumed.120.246983

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire